regulatory filing

Tokyo, August 26, 2026 Daiichi Sankyo announced that the first patient has been dosed in TROPION-Urothelial04, a global Phase...

BOCA RATON, Fla., Aug. 26, 2026 INmune Bio Inc. has advanced Ebstrocel™ toward potential European commercialization after submitting two...

Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...

Hyderabad, India, April 7, 2026 Phase 3 Trial Confirms Biosimilar Equivalence In a significant milestone for biosimilar drug development,...

THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints...

SAN DIEGO, Oct. 1, 2025 — Evofem Biosciences announced that its Middle East partner has submitted an application to...